'Friends of Cancer Research' Will Lead New Public Education Campaign

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 5 No 9
Volume 5
Issue 9

BETHESDA, Md--As part of its resolution commemorating the 25th anniversary of the National Cancer Act, the National Cancer Advisory Board (NCAB) has voted to initiate a 1-year public education program to reaffirm the national commitment to cancer research.

BETHESDA, Md--As part of its resolution commemorating the 25thanniversary of the National Cancer Act, the National Cancer AdvisoryBoard (NCAB) has voted to initiate a 1-year public education programto reaffirm the national commitment to cancer research.

Leading the campaign will be the newly formed Friends of CancerResearch, an organization that includes almost every US cancergroup. Dr. Ellen Sigal, PhD, president of Sigal Environmentaland a member of the NCAB subcommittee on basic and environmentalcancer research, will head the new group.

The goal of the campaign is to mobilize public support for cancerresearch, by meeting the following objectives:

  • Demonstrating the benefits of cancer research.
  • Illustrating the need for answers to the disease.
  • Explaining the investment needed for the task ahead.

Said Dr. Sigal: "This year's 25th anniversary of the NationalCancer Act offers the fulcrum for a major, year-long public awarenesscampaign, combining news events and targeted media hits, thatwill build support for an enhanced national commitment to cancerresearch."

The educational campaign will be launched around September ata major cancer research center, and will have a message alongthe lines of "only research cures cancer."

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
Specialties including neurosurgery, radiation oncology, and neuro-rehabilitation all play a notable role in the care of patients with brain tumors.
Treatment-related toxicities during neuro-oncology therapy appear well managed with dose modifications and treatment cycle holds.
The phase 3 NIVOSTOP trial evaluated an anti–PD-1 immunotherapy, nivolumab, in a patient population similar in the KEYNOTE-689 trial.
CAR T-cell therapies appear to be an evolving modality in the treatment of those with intracranial tumors, said Sylvia Kurz, MD, PhD.
Opportunities to further reduce relapses include pembrolizumab-based combination therapy and evaluating the agent’s contribution before and after surgery.
For patients with locally advanced head and neck cancers, the current standard of care for curative therapy has a cure rate of less than 50%.
According to Maurie Markman, MD, patient-reported outcomes pertain to more relevant questions surrounding the impact of therapy for patients.
CancerNetwork® spoke with Neha Mehta-Shah, MD, MSCI, about the clinical landscape for patients undergoing treatment for rare lymphomas.
Related Content